AN2 Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
ANTX$4.33+8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
(in thousands)
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows used in operating activities | ||
| Net loss | $(26,170) | $(26,464) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 3,405 | 4,846 |
| Net accretion of discount on investments | (377) | (953) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 489 | 1,353 |
| Accounts payable | (1,358) | (1,091) |
| Accrued compensation | (876) | 68 |
| Accrued liabilities | (2) | (1,749) |
| Other current liabilities | (284) | (608) |
| Net cash used in operating activities | (25,173) | (24,598) |
| Cash flows from investing activities | ||
| Purchases of investments | (49,804) | (37,863) |
| Maturities of investments | 29,993 | 59,000 |
| Net cash (used in) provided by investing activities | (19,811) | 21,137 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in the 2026 Private Placement, net of placement agent fees and other offering costs | 21,878 | — |
| Proceeds from issuance of pre-funded warrants in the 2026 Private Placement, net of placement agent fees and other offering costs | 15,361 | — |
| Proceeds from issuance of common stock in the 2026 ATM Offering, net of commissions and offering costs | 7,961 | — |
| Payment of deferred offering costs related to the 2026 ATM Offering | (304) | — |
| Proceeds from issuance of common stock under the ESPP | 111 | 86 |
| Proceeds from exercise of stock options | 243 | 27 |
| Net cash provided by financing activities | 45,250 | 113 |
| Net increase (decrease) in cash and cash equivalents | 266 | (3,348) |
| Cash and cash equivalents at the beginning of the period | 19,941 | 21,351 |
| Cash and cash equivalents at the end of the period | $20,207 | $18,003 |
| Supplemental disclosure of non-cash financing items | ||
| 2026 Private Placement offering costs included in accrued liabilities | $75 | $— |
AN2 Therapeutics, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.